View More View Less
  • 1 Medical School Faculty, Semmelweis University 2nd Department of Medicine Szentkirályi u. 46 H-1088 Budapest Hungary
Restricted access

Cardiovascular mortality rate is increasing all over the world. One of the most important aetiological factors of the lethal outcome is diabetes mellitus. Medicines that can be used for treating this disease include agents which increase insulin secretion (insulin secretagogues), enhance the effect of insulin (insulin sensitizers), or inhibit glucose absorption. All these can be used as monotherapy and in various combinations as well. In the practice, the combination of rosiglitazone and glimepiride seems to be very useful. As each component exerts its activity on different target points, they complement each other well. Glimepiride stimulates insulin secretion in the beta cells, and leads to a reduction of blood glucose levels, while rosiglitazone stimulates peroxisome proliferators-activated receptor-gamma and improves insulin resistance at the vascular and metabolically active cells. The combination of glimepiride and rosiglitazone is usually well tolerated by the patients, and the fix combination also improves their adherence to therapy.

  • Fehér J., Lengyel G.: Mortality from nutrition and cardiovascular diseases (In Hungarian). Orv. Hetil., 2006, 32 , 1491–1496.

    Lengyel G. , 'Mortality from nutrition and cardiovascular diseases (In Hungarian) ' (2006 ) 32 Orv. Hetil. : 1491 -1496.

    • Search Google Scholar
  • Derosa, G., Cicero, A. F. G., D’Angelo, A. et al.: Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens. Res., 2005, 28 , 917–924.

    D’Angelo A. , 'Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride ' (2005 ) 28 Hypertens. Res. : 917 -924.

    • Search Google Scholar
  • Fukuen, S., Iwaki, M., Yasui, A. et al.: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor agonistic activity. J. Biol. Chem., 2005, 280 , 23653–23659.

    Yasui A. , 'Sulfonylurea agents exhibit peroxisome proliferator-activated receptor agonistic activity ' (2005 ) 280 J. Biol. Chem. : 23653 -23659.

    • Search Google Scholar
  • Pfützner, A., Wilhelm, B., Forst, T.: Rosiglitazone and glimepiride: review of clinical results supporting a fixed dose combination. Vasc. Health Risk Manag., 2007, 3 , 211–220.

    Forst T. , 'Rosiglitazone and glimepiride: review of clinical results supporting a fixed dose combination ' (2007 ) 3 Vasc. Health Risk Manag. : 211 -220.

    • Search Google Scholar
  • Sheehan, M. T.: Current therapeutic options in Type 2 Diabetes Mellitus: A practical Approach. Clin. Med. Res., 2003, 1 , 189–200.

    Sheehan M. T. , 'Current therapeutic options in Type 2 Diabetes Mellitus: A practical Approach ' (2003 ) 1 Clin. Med. Res. : 189 -200.

    • Search Google Scholar
  • Zimmerman, B. R.: Sulfonylureas. Endocrinol. Metab. Clin. North Am., 1997, 26 , 511–522.

    Zimmerman B. R. , 'Sulfonylureas ' (1997 ) 26 Endocrinol. Metab. Clin. North Am. : 511 -522.

  • Fukuen, S., Iwaki, M., Yasui, A. et al.: Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ-agonistic activity. J. Biol. Chem., 2005, 280 , 23653–23659.

    Yasui A. , 'Sulfonylurea agents exhibit peroxisome proliferator-activated receptor γ-agonistic activity ' (2005 ) 280 J. Biol. Chem. : 23653 -23659.

    • Search Google Scholar
  • Damsbo, P., Clauson, P., Marbury, T. C. et al.: A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabet. Care, 1999, 22 , 789–794.

    Marbury T. C. , 'A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients ' (1999 ) 22 Diabet. Care : 789 -794.

    • Search Google Scholar
  • DeFronzo, R. A., Goodman, A. M., The Multicenter Metformin Study Group: Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N. Engl. J. Med., 1995, 333 , 541–549.

    Goodman A. M. , 'Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus ' (1995 ) 333 N. Engl. J. Med. : 541 -549.

    • Search Google Scholar
  • Hundal, R. S., Krssak, M., Dufour, S. et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49 , 2063–2069.

    Dufour S. , 'Mechanism by which metformin reduces glucose production in type 2 diabetes ' (2000 ) 49 Diabetes : 2063 -2069.

    • Search Google Scholar
  • Abbasi, F., Carantoni, M., Chen, Y. D. et al.: Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabet. Care, 1998, 21 , 1301–1305.

    Chen Y. D. , 'Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin ' (1998 ) 21 Diabet. Care : 1301 -1305.

    • Search Google Scholar
  • Palumbo, P. J.: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J. Diabet. Comp., 1998, 12 , 110–119.

    Palumbo P. J. , 'Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus ' (1998 ) 12 J. Diabet. Comp. : 110 -119.

    • Search Google Scholar
  • UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352 , 854–865.

    'Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) ' (1998 ) 352 Lancet : 854 -865.

    • Search Google Scholar
  • Garber, A. J., Duncan, T. G., Goodman, A. M. et al.: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 1997, 103 , 491–497.

    Goodman A. M. , 'Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial ' (1997 ) 103 Am. J. Med. : 491 -497.

    • Search Google Scholar
  • Lebovitz, H. E., Kreider, M., Freed, M. I.: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabet. Care, 2002, 25 , 815–821.

    Freed M. I. , 'Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction ' (2002 ) 25 Diabet. Care : 815 -821.

    • Search Google Scholar
  • Ovalle, F., Bell, D. S. H.: Effect of rosiglitazone versus insulin on the pancreatic cell function of subjects with type 2 diabetes. Diabet. Care, 2004, 27 , 2585–2589.

    Bell D. S. H. , 'Effect of rosiglitazone versus insulin on the pancreatic cell function of subjects with type 2 diabetes ' (2004 ) 27 Diabet. Care : 2585 -2589.

    • Search Google Scholar
  • Viberti, G., Kahn, S. E., Greene, D. A. et al.: A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabet. Care, 2002, 25 , 1737–1743.

    Greene D. A. , 'A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes ' (2002 ) 25 Diabet. Care : 1737 -1743.

    • Search Google Scholar
  • Freed, M. I., Ratner, R., Marcovina, S. M. et al.: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am. J. Cardiol., 2002, 90 , 947–952.

    Marcovina S. M. , 'Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus ' (2002 ) 90 Am. J. Cardiol. : 947 -952.

    • Search Google Scholar
  • Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R. et al.: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med., 2001, 134 , 61–71.

    Granda-Ayala R. , 'Nonhypoglycemic effects of thiazolidinediones ' (2001 ) 134 Ann. Intern. Med. : 61 -71.

    • Search Google Scholar
  • Raji, A., Plutzky, J.: Insulin resistance, diabetes and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr. Cardiol. Rep., 2002, 4 , 514–521.

    Plutzky J. , 'Insulin resistance, diabetes and atherosclerosis: thiazolidinediones as therapeutic interventions ' (2002 ) 4 Curr. Cardiol. Rep. : 514 -521.

    • Search Google Scholar
  • Mittermayer, F., Schaller, G., Pleiner, J. et al.: Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction.; M. J. Clin. Endocrinol. Metab., 2007 May 1; [Epub ahead of print.

  • Kerenyi, Zs., Samer, H., James, R. et al.: Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabet. Res. Clin. Prac., 2004, 63 , 213–223.

    James R. , 'Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus ' (2004 ) 63 Diabet. Res. Clin. Prac. : 213 -223.

    • Search Google Scholar
  • Home, P. D., Pocock, S. J., Beck-Nielsen, H. et al.: Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. NEJM, 2007, 357 , 28–38.

    Beck-Nielsen H. , 'Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis ' (2007 ) 357 NEJM : 28 -38.

    • Search Google Scholar
  • Kim, H. J., Kang, E. S., Kim, D. J. et al.: Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin. Endocrin., 2007, 66 , 282–289.

    Kim D. J. , 'Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus ' (2007 ) 66 Clin. Endocrin. : 282 -289.

    • Search Google Scholar
  • Psaty, B. M., Furberg, C. D.: The record on rosiglitazone and the risk of myocardial infarction. N. Engl. J. Med., 2007, 357 , 67–69. Epub 2007 Jun 5.

    Furberg C. D. , 'The record on rosiglitazone and the risk of myocardial infarction ' (2007 ) 357 N. Engl. J. Med. : 67 -69.

    • Search Google Scholar
  • de Dios, S. T., Frontanilla, K. V., Nigro, J. et al.: Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J. Diabet. Comp., 2007, 21 , 108–117.

    Nigro J. , 'Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents ' (2007 ) 21 J. Diabet. Comp. : 108 -117.

    • Search Google Scholar
  • de Dios, S. T., Bruemmer, D., Dilley, R. J. et al.: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery and saphenous vein smooth muscle cell proliferation. Circulation, 2003, 107 , 2548–2550.

    Dilley R. J. , 'Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery and saphenous vein smooth muscle cell proliferation ' (2003 ) 107 Circulation : 2548 -2550.

    • Search Google Scholar
  • Haberbosch, W.: Einfluss der Thiazolidindione auf die diabetestypische Dyslipidämie. Wirken alle gleichermaßen gefäßprotektiv? Herz, 2007, 32 , 51–57.

    Haberbosch W. , 'Einfluss der Thiazolidindione auf die diabetestypische Dyslipidämie. Wirken alle gleichermaßen gefäßprotektiv? ' (2007 ) 32 Herz : 51 -57.

    • Search Google Scholar
  • Jermendy, Gy.: New fix combination in type 2 diabetes mellitus (In Hungarian). Med. Trib., 2007. 18.

  • Pfützner, A., Schöndorf, T. T., Seidel, D. et al.: Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabol. Clin. Exp., 2006, 55 , 20–25.

    Seidel D. , 'Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride ' (2006 ) 55 Metabol. Clin. Exp. : 20 -25.

    • Search Google Scholar

Hungarian Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1788-6139 (Print)
ISSN 1789-0403 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 2 0 0
Jun 2021 2 0 0
Jul 2021 2 0 0
Aug 2021 2 0 0
Sep 2021 1 0 0
Oct 2021 0 0 0
Nov 2021 0 0 0